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Background: Graft-versus-host disease (GVHD) is initiated 
when alloreactive donor T cells are primed by host APCs to 
undergo clonal expansion and maturation. Since there is a 
controversy regarding the role of nonhematopoietic cells in 
GVHD, we wanted to investigate the influence of MHC dis-
parity on nonhematopoietic cells on the pathogenesis of 
GVHD in the MHC-haplomismatched C57BL/6 (H-2
b) or 
DBA/2 (H-2
d)→unirradiated (C57BL/6×DBA/2) F1(BDF1; 
H-2
b/d) murine model of acute GVHD (aGVHD) or chronic 
GVHD (cGVHD). Methods: We generated (BDF1→C57BL/6), 
(BDF1→DBA/2), and (BDF1→BDF1) chimeras and exam-
ined GVHD-related parameters and donor cell engraftment 
in those chimeras. Results: Using this experimental system, 
we found that 1) severe aGVHD across MHC Ag barrier de-
pends on the expression of nonhematopoietically rather than 
hematopoietically derived alloAgs for maximal GVHD mani-
festations; 2) host APCs were sufficient to break B cell toler-
ance to self molecules in cGVHD, whereas host APCs were 
insufficient to induce autoimmunity in aGVHD; 3) donor cell 
engraftment was greatly enhanced in the host with 
MHC-matched nonhematopoietic cells. Conclusion:  Taken 
together, our results provide an insight into how MHC dis-
parity on GVHD target organs contribute to the patho-
genesis of GVHD.
[Immune Network 2010;10(2):46-54]
INTRODUCTION
In the parent-into-F1 graft-versus host disease (GVHD) model, 
the  genetic  background  of  donor  strains  is  critical  in  de-
termining the outcome of GVHD (1,2). For example, the in-
fusion of donor T cells from the DBA/2 strain into an uni-
rradiated (C57BL/6×DBA/2)F1 (BDF1) mouse induces chronic 
GVHD (cGVHD), whereas the infusion of T cells of the other 
parent,  C57BL/6  (B6),  induces  acute  GVHD  (aGVHD)  (3). 
CD4
＋ T cells of the DBA/2 strain activate and expand host 
B  cells  with  an  autoreactive  potential,  resulting  in  systemic 
lupus  erythematosus  (SLE)-like  symptoms  such  as  autoAb 
production and glomerulonephritis (4). In aGVHD, not only 
do donor CD8
＋ T cells eliminate host hematopoeietic cells, 
particularly host B cells, to induce massive engraftment of do-
nor  cells,  but  also  donor  CD8
＋ T  c e l l s  a t t a c k  s o l i d  o r g a n s 
together with immune cells regulated by donor CD4
＋ T cells, 
resulting in loss of body weight (1). It seems that donor CD8
＋ 
T  cell  anergy  is  a  restriction  factor  for  the  development  of 
cGVHD (5,6). Even though donor CD4
＋ T cells have the abil-
ity to break host B cell tolerance in both cGVHD and aGVHD, 
donor CD8
＋ T cells have a different fate after transfer into 
the host; donor CD8
＋ T cells are rapidly eliminated from the 
host and the remaining cells fall into anergy in cGVHD (5,6), 
whereas donor CD8
＋ T cells are differentiated into effector 
T cells that have the ability to delete host B cells including 
potential autoreactive B cells in aGVHD, thus depriving the 
host  of  the  opportunity  to  produce  autoAb  (7-9).
    It  is  controversial  whether  cognate  interactions  between 
TCRs  and  MHC  on  nonhematopoietic  target  tissues  are  re-
quired for GVHD (10-13). In MHC-mismatched GVHD, TCRs Host Nonhematopoietic Cells in GVHD
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can directly recognize recipient MHC (10-12). Teshima et al. 
(13) have shown that CD4-mediated GVHD, and to a lesser 
extent CD8-mediated GVHD do not require such direct inter-
actions, suggesting that the direct allorecognition of donor T 
cells on host APCs is critical in GVHD. It is not known how 
donor  B6  T  cells  induce  GVHD  in  the  B6→BDF1 a G V H D  
model. In this study, F1→parent chimeras were used to eluci-
date  the  involvement  of  alloAg  expression  by  non-
hematopoietic tissues in the B6→BDF1 aGVHD model. Our 
results indicate that aGVHD induced solely by alloreactive do-
nor T cells depends on the expression of nonhematopoieti-
cally  rather  than  hematopoietically  derived  alloAgs.
MATERIALS AND METHODS
Mice
Female  DBA/2  (H-2
d) and BDF1 (H -2
b/d) mice, 7∼8 wk of 
age,  were  purchased  from  Orient  (Seoul,  Korea).  All  mice 
were maintained in pathogen-free conditions. These studies 
were  approved  by  institutional  animal  care  committee.
Abs and reagents
The following FITC-, PE-, PerCP- or biotin-conjugated mAbs 
to mouse proteins were purchased from BD Biosciences (San 
Diego,  CA):  CD4,  CD8,  B220,  H-2K
b,  H-2K
d,  CD62L.  HRP- 
conjugated rat anti-mouse IgG 1 Abs also were purchased from 
BD  Biosciences.
Bone marrow (BM) reconstitution
BM cells were collected by flushing femurs and tibias from 
BDF1 mice into MACS buffer (1×PBS containing 5 mM EDTA 
and 3% BSA). After erythrocyte lysis in hemolysis buffer (144 
mM NH4Cl and 17 mM Tris-HCl, pH 7.2), BM cell were in-
cubated with biotinylated anti-CD3 mAb for 20 min on ice, 
washed once, then incubated with streptavidin-conjugated mi-
crobeads (Miltenyi Biotech, Auburn, CA) for 20 min at 4
oC. 
Cells  were  depleted  of  CD3
＋ c e l l s  u s i n g  M A C S  b u f f e r .  
Remaining  CD3
＋ c e l l s  r o u t i n e l y  c o m p r i s e d  l e s s  t h a n  1 %  o f 
BM cells. Recipient BDF1 mice received 12 gray (Gy) irradi-
ation  from  a  cesium  irradiator  and  were  reconstituted  with 
5×10
6 T - c e l l - d e p l e t e d  B M  f r o m  B D F 1 m i c e .
Induction of GVHD
GVHD was induced as described previously (14-16). In brief, 
single-cell  suspensions  in  PBS  were  prepared  from  spleens 
and  lymph  nodes  of  normal  B6  or  DBA2  donors,  filtered 
through a sterile mesh (BD Biosciences), and washed. After 
the erythrocytes were lysed in hemolysis buffer, the remain-
ing  cells  were  resuspended  at  8×10
7  cells/0.2  ml  in  PBS. 
GVHD was induced by transfer of 8×10
7 of spleens/lymph 
node  cells  into  the  tail  vein  of  unirradiated  BDF1 r e c i p i e n t  
mice  at  12  wk  after  BM  transplantation.
ELISA
M i c e  w e r e  b l e d  f r o m  t h e  t a i l  v e i n ,  a n d  s e r u m  t i t e r s  o f  a n-
ti-DNA IgG1 were assessed by ELISA. Plates (96-well) were 
incubated overnight at 4
oC with 100 μl salmon sperm DNA 
(Sigma-Aldrich, St. Lois, MO) at a concentration of 10 μg/ml. 
After blocking with 2% BSA, the plates were incubated with 
100  μl  serially  diluted  serum  samples  for  1  h  at  room 
temperature. They were washed three times with PBS con-
taining 0.1% Tween 20, and HRP-conjugated anti-mouse IgG1 
was added to each well and the plates were kept at room 
temperature for 1 h. They were washed again with the same 
solution and color was developed in 100 μl 3,5,3',5'-tetrame-
thylbenzene substrate (Pierce, Rockford, IL) for 10∼15 min 
and stopped by adding 100 μl of 1 N HCl. The plates were 
then  read  at  450  nm  with  a  Wallac  Vector  1420  Multilabel 
Counter (PerkinElmer, Waltham, MA). OD  values at a 1/10 
dilution  of  sera  were  presented.
Flow cytometry
The spleens of GVHD mice were harvested on the indicated 
days after parental cell transfer. After lysis of the erythrocytes, 
the splenocytes were preincubated in a blocking buffer (PBS 
containing  2.4G2  mAb/0.2%  BSA/0.1%  sodium  azide),  and 
then  incubated  with  the  relevant  mAbs  for  30  min  at  4
oC. 
Finally,  they  were  washed  twice  with  staining  buffer  (PBS 
containing  0.2%  BSA/0.1%  sodium  azide)  and  analyzed  by 
FACscan  (BD  Biosciences).
Histopathology
Formalin-fixed  kidney,  liver,  and  large  intestine  were  em-
bedded  in  paraffin,  and  5  μm  thick  sections  were  stained 
with H&E and evaluated by light microscopy. Slides for liver 
and  large  intestine  were  coded  and  further  examined  in  a 
blinded  fashion  by  one  individual  (H.J.C.),  using  a  semi-
quantitative system for abnormalities known to be associated 
with aGVHD (17,18). In brief, samples of liver tissue was per-
formed  by  scoring  14  pathologic  features,  including  in-
flammatory infiltrates in bile ducts and portal tracts, vascular 
endothelialitis,  and  hepatocellular  damage  as  previously Host Nonhematopoietic Cells in GVHD
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Figure 1. Confirmation of BM reconstitution. B6, DBA/2 and BDF1
mice received 12 Gy irradiation and were reconstituted with 5×10
6
T cell-depleted BDF1 BM cells. PBMCs were analyzed by flow 
cytometry at days 45 and 55 after cell transfer. Percent of donor cells
were counted by staining PBMCs with anti-H-2K
b or H-2K
d mAbs 
(n=10∼20 per group).
reported. A severity scale from one to four was used where 
0=normal, 0.5=rare scattered, 1=minimal or focal, 2=mild and 
more  diffuse,  3=moderate  damage,  and  4=severe  damage. 
Scores for each individual feature were added to yield a com-
posite score of liver pathology. Colon abnormalities were as-
sessed by examining crypt regeneration, surface coloncytes, 
colonocyte  vacuolization,  surface  colonocyte  attenuation, 
crypt  cell  apoptosis,  outright  crypt  destruction,  and  lamina 
propria lymphocytic infiltrate. The scoring system denoted 0 
as normal, 0.5 as focal and rare, 1.0 as focal and mild, 2.0 
as diffuse and mild, 3.0 as diffuse and moderate, and 4.0 as 
diffuse  and  severe.  Scores  were  added  to  provide  a  total 
score for each specimen. Only after scoring was performed 
were  codes  broken  and  data  compiled.
Statistical analysis
The Student's t test was used to determine the statistical sig-
nificance of differences between experimental groups. Error 
bars represent SD of the mean. Log-rank Mantel-Cox test was 
used  for  survival  curves.
RESULTS
The parent-into-unirradiated GVHD model is unique among 
GVHD models in that the development of GVHD is initiated 
only  by  alloreactivity  without  inflammation  induced  by 
preconditioning. This property provides a less complication 
in interpreting experimental data and finds its usefulness in 
an experimental tool to dissect a variety of issues related to 
immune tolerance to alloAgs. In this study, we wanted to in-
vestigate the roles of nonhematopoietic cells in GVHD in the 
MHC-haplomismatched  B6  or  DBA/2→unirradiated  BDF1 
murine  model  of  aGVHD  or  cGVHD.  We  created  (BDF1→
B6), (BDF1→DBA/2), or (BDF1→BDF1) chimeras. In this ex-
periment system, allogeneic host APCs could stimulate donor 
T  cells,  regardless  of  MHC  mismatch  in  nonhematopoietic 
cells. PBMCs were ＞90% donor-derived in BDF1→B6 or DBA/2 
mice by 8 wk after BM transfer (Fig. 1). We induced aGVHD 
in  three  sets  of  chimeras  by  transferring  B6  spleen/lymph 
node cells. BDF1→DBA/2 chimeras had most severe aGVHD 
as measured by loss of body weight and histologic analysis 
of aGVHD target organs (Fig. 2). Except for earlier death in 
a small portion of mice, BDF1→B6 chimeras barely showed 
clinical  and  pathologic  symptoms  of  aGVHD.  The  earlier 
death could be due to a large quantity of cytokines produced 
when B6 donor T cells killed host BDF1 hematopoietic cells 
(also see Fig. 2; Ref 13). BDF1→BDF1 control mice had mild-
e r  a G V H D  t h a n  B D F 1→DBA/2  chimeras  but  more  severe 
hepatic GVHD than BDF1→B6 chimeras. Taken together, our 
results indicate that severe aGVHD mediated by donor T cells 
depends  on  the  expression  of  alloAgs  in  nonhematopoietic 
cells. A similar conclusion has been reached in CD8
＋ T cell- 
or CD4
＋ T cell-mediated aGVGD across minor histocompati-
bility  Ag  (miHA)  barrier  (19,20).
    In  our  experimental  system,  TCRs  of  donor  B6  T  cells 
could  recognize  intact  BDF1 M H C  o n  h o s t  h e m a t o p o i e t i c  
cells. Alloreactive donor T cells generated from these inter-
actions  could  remove  host  hematopoietic  cells  and  make  a 
niche for donor hematopoietic stem cells. As shown in Fig. 
3,  MHC  disparity  on  nonhematopoietic  cells  had  a  reverse 
correlation with donor cell engraftment. Even though aGVHD 
was  not  evident  in  BDF1→B 6  c h i m e r a s ,  m o r e  t h a n  9 0 %  o f 
splenocytes were of donor origin. In contrast, despite of se-
vere aGVHD, DBF1→DBA/2 chimeras had the least extent of 
donor cell engraftment among the three sets of chimeras. Our 
data  indicate  that  MHC  disparity  on  nonhematopoietic  cells 
is  a  greater  hurdle  to  donor  cell  engraftment. 
    It is thought that alloreactive donor T cells exhibit an acti-
vation  status  in  MHC-mismatched  GVHD,  because  they  re-
ceive sustained allostimulation. Consistent with this hypoth-
esis, a greater number of activated CD4
＋ T cells and CD8
＋ 
T cells (CD62L
low) were contained in the spleen of BDF1→
D B A / 2  c h i m e r a s  a n d  p o s i t i v e  c o n t r o l s  ( B D F 1→BDF1 m i c e ) ,  
compared with BDF1→B6 mice (Fig. 4). Therefore, our result Host Nonhematopoietic Cells in GVHD
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Figure 2. MHC disparity on nonhematopoietic cells exacerbates aGVHD. Eighty-four days after BM reconstitution, aGVHD was induced by 
transferring 8×10
7 B6 spleen/lymph node cells into three sets of mice (n=20 per group). (A) Loss of body weight. (B) Percent of survival. (C)
Pathological scores for livers and colons. Organs were harvested at day 54 after disease induction (n=5∼8 per group). 
†p＜0.001, **p＜0.01
and *p＜0.05 between the indicated groups.
suggests that alloreactive T cells in BDF1→B6 chimeras may 
remain quiescent after allogenic host hemtopoietic cells are 
removed. 
  The DBA/2→BDF1 cGVHD model has been extensively uti-
lized  to  study  how  alloimmunity  breaks  B-cell  tolerance  to 
self molecules (21). Using this model, we wanted to examine 
the effect of MHC disparity on nonhematopoietic cells on au-
toimmunity and donor cell engraftment. cGVHD was induced 
by transferring DBA/2 spleen/lymph node cells into BDF1→
B6, BDF1→DBA/2, and BDF1→BDF1 chimeras. As shown in 
Fig. 5A, DBA/2 donor T cells were equally potent in inducing 
production of IgG1 anti-DNA autoAb in all of the three sets 
of chimeras, suggesting that MHC disparity on hematopoietic 
cells are sufficient for but MHC disparity on nonhematopoietic 
cells  are  not  involved  in  the  development  of  cGVHD. 
Furthermore, it seems that mortality due to cGVHD was not 
influenced by MHC disparity on nonhematoietic cells: there 
was no difference in the rate of mortality between BDF1→
DBA/2 and BDF1→B6 chimeras (Fig. 5B). Histopathological 
analysis showed that the kidney of either BDF1→DBA/2 or 
BDF1→B6 chimeras had severe glomerulonephritis (Fig. 5C). 
Nontherless,  engraftment  of  donor  lymphocytes,  including 
CD4
＋ T  c e l l s ,  C D 8
＋  T  cells,  and  B  cells,  was  significantly 
higher  in  BDF1→DBA/2  than  in  BDF1→B6  chimeras,  al-
though the two groups had no difference in the percent of 
total donor cell engraftment (Fig. 6). Levels of donor lympho-
c y t e  e n g r a f t m e n t  w e r e  p o s i t i v e l y  c o r r e l a t e d  w i t h  t h e  e x t e n t  
of donor CD8
＋ T cell activation (Fig. 7). These results sug-Host Nonhematopoietic Cells in GVHD
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Figure 3. MHC match on nonhematopoietic cells increases donor cell engraftment in aGVHD. Eighty-four days after BM reconstitution, aGVHD 
was induced by transferring 8×10
7 B6 spleen/lymph node cells into three sets of mice (n=20 per group). Splenocytes were harvested at day
54 after disease induction and stained with anti-H-2K
d plus anti-CD4, anti-CD8 or B220. (A) Percent of total donor cells. (B) Percent of donor
B cells. (C) Percent of donor CD4
＋ T cells. (D) Percent of donor CD8
＋ T cells (n=5∼8 per group). 
†p＜0.001, **p＜0.01 and *p＜0.05 between
the indicated groups.
gest that MHC match on nonhematopoietic cells is critical in 
donor cell engraftment, as shown in the B6→BDF1 aGVHD 
model.
DISCUSSION
I n  t h e  B 6 →BDF1  aGVHD  model,  theoretically,  MHC-hap-
lomismatched host APCs can not only stimulate donor T cells 
through  interactions  between  allo-MHC  and  TCRs  but  also 
present processed alloAgs or self-Ags to donor T cells in the 
context  of  self-MHC.  Our  results  suggest  that,  even  though 
GVHD is initiated by donor T cells after receiving allostimula-
tion  by  host  APCs,  through  the  direct  alloreactive  pathway 
(22), presentation of nonhematopoietically derived alloAgs by 
donor  APCs  is  a  prerequisite  for  the  propagation  of  the 
disease. It seems that (BDF1→B6) chimeras experience tran-
sient cachexia (which sometimes results in mortality) with re-
duced target-tissue injury over time, reflecting an early, lim-
ited  graft-versus-host  response.  This  interpretation  is  con-
sistent with results obtained  from various MHC-matched or- 
mismatched  aGVHD  models  (23-27).
  It is still controversial whether the expression of nonhemato-
poietically  derived  alloAgs  is  required  for  CD4-mediated 
aGVHD. Two sharp contrast results have been reported (13,20). 
Teshima et al. (13) demonstrated in the MHC-disparate bm12
→[B6→B6.MHC  II
−/−]  B M  c h i m e r a  m o d e l  t h a t  a l l o A g  e x -Host Nonhematopoietic Cells in GVHD
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Figure 4. MHC match on nonhematopoietic cells decreases activation of donor T cells in aGVHD. Eighty-four days after BM reconstitution, aGVHD
was induced by transferring 8×10
7 B6 spleen/lymph node cells into three sets of mice (n=20 per group). Splenocytes were harvested at day
54 after disease induction and stained with anti-H-2K
d plus anti-CD62L and anti-CD4 or anti-CD8. (A) Percent of donor CD4
＋CD62L
low T cells.
(B) Percent of donor CD8
＋CD62L
low T cells (n=8 per group). 
†p＜0.001, **p＜0.01 and *p＜0.05 between the indication groups.
Figure 5. MHC disparity on nonhematopoietic cells does not affect the
development of cGVHD. B6, DBA/2 and BDF1 mice received 12 Gy
irradiation and were reconstituted with 5×10
6 T cell-depleted BDF1 
BM cells. Eighty-four days after BM reconstitution, cGVHD was 
induced by transferring 8×10
7 DBA/2 spleen/lymph node cells into 
three sets of mice (n=10 per group). (A) Serum samples were collected
every 2 wk and assayed in duplicate by ELISA for IgG1 anti-DNA 
autoAb. The OD of duplicate samples for each mouse was measured
at 450 nm, using serially diluted serum samples. (B) Percent of survival
(n=10 per group). (C) Histology of kidneys harvested at day 54 after
disease induction. Representative kidney sections are shown for H&E 
staining. *p＜0.05 between the indicated groups.Host Nonhematopoietic Cells in GVHD
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Figure 6. MHC match on nonhematopoietic cells increases donor lymphocyte engraftment in cGVHD. Eighty-four days after BM reconstitution, 
cGVHD was induced by transferring 5×10
6 DBA/2 spleen/lymph node cells into three sets of mice (n=20 per group). Splenocytes were harvested
at day 54 after disease induction and stained with anti-H-2K
b plus anti-CD4, anti-CD8 or B220. (A) Percent of total donor cells. (B) Percent
of donor B cells. (C) Percent of donor CD4
＋ T cells. (D) Percent of donor CD8
＋ T cells (n=5∼8 per group). **p＜0.01 and *p＜0.05 between
the indicated groups.
Figure 7. Donor lymphocyte engraftment correlates with donor CD8
＋ T cell activation in cGVHD. Eighty-four days after BM reconstitution, aGVHD
was induced by transferring 5×10
6 DBA/2 spleen/lymph node cells into three sets of mice (n=10 per group). Splenocytes were harvested at 
day 54 after disease induction and stained with anti-H-2K
b plus anti-CD62L and anti-CD4 or anti-CD8. (A) Percent of donor CD4
＋ CD62L
low
T cells. (B) Percent of donor CD8
＋CD62L
low  T cells (n=8 per group). *p＜0.05 between the indicated groups.Host Nonhematopoietic Cells in GVHD
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pression by the hematopoietic compartment alone was suffi-
cient to obtain lethal GVHD, whereas Jones et al. (20) dem-
onstrated  significantly  diminished  B6  CD4
＋ T  c e l l - m e d i a t e d 
GVHD development when recipient BALB.B mHAs were ex-
clusively derived from cells of the hematopoietic compartment. 
This discrepancy may be due to differences in the allogeneic 
T  cell  response  directed  across  MHC  versus  mHA  barriers, 
most notably the involvement of a much higher alloreactive 
CD4
＋ T cell precursor frequency in the former situation (28). 
In bm12→B6 (20) and similar models (18,29-32), such a vigo-
rous T cell response can rapidly generate high levels of proin-
f l a m m a t o r y  c y t o k i n e s  r e s p o n s i b l e  f o r  i n i t i a t i n g  a c u t e  t i s s u e  
damage in the early post-hematopoietic stem cell transplan-
tation period. However, our results suggest that alloreactive 
T  cells  generated  by  the  exposure  to  allogeneic  host  APCs 
are insufficient to drive fully developed GVHD in the absence 
of  preconditioning.  Therefore,  proinflammatory  cytokines 
produced  as a  result  of  preconditioning  such  as total  body 
irradiation play a critical role in the induction of GVHD, pre-
sumably in synergy with a donor T cell response or/and by 
helping the broadening of the pool of alloreactive donor T 
cells (33-35). In either case, the data suggest that alloreactive 
donor T cells generated from either the direct pathway (by 
allogeneic host APCs) or the indirect pathway (nonhemato-
poietically  derived  alloAgs  are  presented  by  host  or  donor 
APCs) mediate GVHD with great help of proinflammatory cy-
tokines  triggered  by  preconditioning.
  I t  i s  w e l l  k n o w n  t h a t  G V H D ,  i n  p a r t i c u l a r ,  c G V H D ,  h a s  
clinical manifestations of autoimmune disorders (36-38). Our 
observations showing that BDF1→B6 chimeras did not display 
a G V H D  a f t e r  t r a n s f e r  o f  B 6  T  c e l l s  s u g g e s t  t h a t  a l l o g e n e i c  
host  APCs  is  insufficient  to  break  self-tolerance.  Since 
GVHD-induced autoreactivity is donor APC-dependent in irra-
diated  recipient  mice  (39),  and  BDF1  APCs  can  present 
self-Ags to donor B6 T cells in  BDF1→B6  chimeras,  proin-
flammatory cytokines produced as a result of preconditioning 
may facilitate autoimmunity by donor T cells. In such irradi-
ated models, autoimmunity is evolved as aGVHD is progress-
ing  (24).  In  our  cGVHD  model,  alloreactive  donor  T  cells 
(CD4
＋ T cells) rapidly broke B cell tolerance regardless of 
MHC match on nonhematopoietic cells. Therefore, a certain 
genetic  combination  of  MHC disparity  between donors  and 
recipients may be a risk factor for SLE-like cGVHD, especially 
in  patients  with  transient  or  chronic  states  of  mixed 
chimerism. However, clinical correlates of these observations 
should  be  established.
  I n  t h e  B 6 →BDF1 aGVHD model, alloreactive donor CD8
＋ 
T  cells  kill  host  hematopoietic  cells  for  donor  cell  engra-
ftment. Surprisingly, donor cell engraftment is not positively 
correlated with the severity of GVHD. This observation sug-
gests  that  donor-recipient  genetic  combinations  may  exist 
where donor T cells do not induce GVHD with intact donor 
cell engraftment and thus intact graft-versus-leukemia effects. 
It will be important to search for a genetic factor that governs 
donor  cell  engraftment.
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